Castle Biosciences (CSTL) EBIT (2018 - 2026)

Castle Biosciences has disclosed EBIT across 9 years of filings, most recently posting -$18.4 million for Q1 2026.

• EBIT for Q1 2026 came in at -$18.4 million, up 34.09% year-over-year; the trailing twelve-month figure through Mar 2026 was -$33.3 million (down 141.45% YoY), and the FY2025 annual result was -$42.8 million, down 593.77% from the prior year.
• EBIT came in at -$18.4 million for Q1 2026 at Castle Biosciences, down from -$3.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $5.1 million in Q3 2024 to a low of -$31.5 million in Q1 2023.
• The 5-year median for EBIT is -$6.8 million (2025), against an average of -$11.4 million.
• Across the five-year window, EBIT slumped 472.27% in 2022 and soared 171.58% in 2024, its largest moves.
• Castle Biosciences' EBIT stood at -$22.8 million in 2022, then surged by 75.22% to -$5.7 million in 2023, then surged by 171.58% to $4.0 million in 2024, then plunged by 194.49% to -$3.8 million in 2025, then plunged by 380.98% to -$18.4 million in 2026.
• The last three EBIT figures came in at -$18.4 million (Q1 2026), -$3.8 million (Q4 2025), and -$6.8 million (Q3 2025), per Business Quant data.